# Reviewer Report

## Overall status

`VALID WITH BOUNDED CLAIMS`.

## P0

None. No label, feature-selection, preprocessing, threshold, entity, or prediction-row leakage was found. No infeasible candidate can win the Q4 rank.

## P1

None. Every task has a baseline, held-out validation, retained fold evidence, dependency link, and explicit claim boundary.

## P2 limitations

1. The source does not define whether CYP3A4=1 or 0 is the desirable state. The candidate changes from TEST026 to TEST019 when this direction changes; the report therefore refuses an unconditional recommendation.
2. Q2 Extra Trees has a large training/validation gap. Outer validation remains strong, but candidate activity is kept as a surrogate with fold uncertainty.
3. The applicability domain is empirical descriptor support. It does not prove chemical synthesizability, biological efficacy, or safety.
4. The 50 prediction rows have no labels, so final candidate performance cannot be externally verified in this run.

## Skill assessment

The existing feature-set, imbalance, evaluation-semantics, structured-feasibility, evidence-provenance, and reviewer rules combine successfully. Generic applicability-domain guidance is terse, but the run closes the boundary with the problem contract and general validation rules; no actual P0/P1 workflow failure results. This is a P2 documentation weakness, not a confirmed generalizable integration gap.

## First meaningful failure

`NONE`. The first material boundary is a problem-specific CYP3A4 desirability ambiguity, isolated before ranking and sensitivity-tested. Failure level: `NONE`; gap candidate: `NO_CONFIRMED_GAP`.
